Clinical Trial Update: BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 BrUOG 355 trial evaluating nivolumab with tailored radiation therapy and concurrent cisplatin in cervical cancer was terminated; results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• nivolumab (nivolumab)

Snippet

Sponsor: Brown University | Conditions: Cervical Cancer | Phase 2 | Status: TERMINATED | Results posted: 2022-04-26